SCHEMBL22200466

SCHEMBL22200466

CC(C)n1c(=O)c(-c2ccc(NSCC34CCC(CC3)C4)c(F)c2)nc2cnc(N)nc21

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 4/20 0.40
TLR9 Q9NR96 8/20 0.34
TLR8 Q9NR97 8/20 0.34
TLR7 Q9NYK1 8/20 0.34
CYP1A2 P05177 5/20 0.34
CYP3A4 P08684 3/20 0.34
MTOR P42345 3/20 0.33
HSD17B10 Q99714 3/20 0.32
ALDH1A1 P00352 3/20 0.32
USP2 O75604 1/20 0.32
TSHR P16473 2/20 0.31
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
CYP2D6 P10635 1/20 0.31
CASP1 P29466 1/20 0.31
CASP7 P55210 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25035604 0.86 ERN1 (0.48) ERN1TLR9TLR8TLR7CYP1A2
SCHEMBL22200836 0.85 ERN1 (0.39) ERN1TLR9TLR8TLR7CYP1A2
SCHEMBL22200790 0.85 ERN1 (0.42) ERN1TLR9TLR8TLR7CYP1A2
SCHEMBL22200827 0.85 ERN1 (0.42) ERN1TLR9TLR8TLR7CYP1A2
SCHEMBL22200794 0.84 ERN1 (0.43) ERN1TLR9TLR8TLR7CYP1A2
SCHEMBL22200654 0.84 ERN1 (0.42) ERN1TLR9TLR8TLR7CYP1A2
SCHEMBL22200470 0.84 ERN1 (0.42) ERN1TLR9TLR8TLR7CYP1A2
SCHEMBL22200643 0.83 ERN1 (0.42) ERN1TLR9TLR8TLR7CYP1A2
SCHEMBL22200796 0.83 ERN1 (0.40) ERN1TLR9TLR8TLR7CYP1A2
SCHEMBL22200356 0.82 ERN1 (0.41) ERN1CYP1A2CYP3A4MTORHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed